Tandem Diabetes Care
TNDM
273 hedge funds and large institutions have $2.77B invested in Tandem Diabetes Care in 2023 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 117 increasing their positions, 92 reducing their positions, and 53 closing their positions.
126% more call options, than puts
Call options by funds: $9.71M | Put options by funds: $4.3M
27% more repeat investments, than reductions
Existing positions increased: 117 | Existing positions reduced: 92
5.51% more ownership
Funds ownership: 99.98% → 105.49% (+5.5%)
4% less capital invested
Capital invested by funds: $2.89B → $2.77B (-$120M)
7% less funds holding
Funds holding: 295 → 273 (-22)
36% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 53
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$118M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$45.8M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$38.1M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$34.3M |
| 5 |
Morgan Stanley
New York
|
+$18.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$58.1M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$39.6M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$16.2M |
| 4 |
GIP
Granite Investment Partners
El Segundo,
California
|
-$14.4M |
| 5 |
Axa
Paris,
France
|
-$14M |
TNDM Hedge Fund Activity: Q1 2023 in Review
273 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Tandem Diabetes Care (TNDM) for Q1 2023, worth a combined $2.77B — down 4.2% from $2.89B a quarter earlier.
Sellers outnumbered buyers: 53 funds closed out of TNDM and 34 opened new positions — a net loss of 19 holders — while 92 trimmed existing stakes and 117 added.
The largest buyer was BlackRock, adding an estimated $118M. The largest seller was Fidelity Investments, cutting an estimated $58.1M.
- 273 institutional investors held Tandem Diabetes Care (TNDM) as of Q1 2023, down from 295 in Q4 2022.
- Funds reported $2.77B of Tandem Diabetes Care stock for Q1 2023, down 4.2% quarter-over-quarter.
- 34 funds opened new Tandem Diabetes Care positions in Q1 2023 and 53 closed out, a net change of -19 holders.
- The largest Tandem Diabetes Care buyer in Q1 2023 was BlackRock, an estimated $118M added.
- The largest Tandem Diabetes Care seller in Q1 2023 was Fidelity Investments, an estimated $58.1M sold.
Based on aggregated 13F filings for Q1 2023.